Summary Comments
- Most frequently detected viruses in June 2024 (all age groups):
- Rhino/Enterovirus: 21.1%
- Influenza A: 18.4%
- Epidemiological Week 1–26:
- SARS-CoV-2: Stable over last 4 weeks
- Influenza A: Peaked at 43.6% (week 20), declined to 8.3% by week 26
- Influenza B: Rose to 8.9% by week 26; 24% of positive influenza specimens were Influenza B
- RSV: Peaked at 27.8% (week 13), declined to 10% by week 26
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
May 2024:
- Rhino/Enterovirus: 21.1%
- Influenza A: 39.4%
- RSV: 13.5%
- Rhinovirus: 9.7%
- SARS-CoV-2: 4.4%
- Influenza B: 3.0%
- Adenovirus: 2.3%
- Parainfluenza 1–4: 2.1%
- Human metapneumovirus: 2.4%
- Coronavirus (non-SARS-CoV-2): 3.1%
June 2024:
- Rhino/Enterovirus: 21.1%
- Influenza A: 18.4%
- RSV: 13.7%
- Rhinovirus: 9.6%
- SARS-CoV-2: 6.5%
- Influenza B: 6.1%
- Adenovirus: 5.2%
- Parainfluenza 1–4: 1.9%
- Human metapneumovirus: 3.1%
- Coronavirus (non-SARS-CoV-2): 7.3%
Atypical Bacterial Pathogens (Weeks 1–26)
Detected Pathogens:
- B. pertussis
- M. pneumoniae
- C. pneumoniae
- No cases of Legionella pneumophila in June
Age Distribution:
Bordetella pertussis:
- 0–6 months: 16%
- 6–12 months: 7%
- 1–5 years: 30%
- 6–12 years: 18%
- 13–18 years: 3%
- 19–64 years: 18%
65 years: 8%
Mycoplasma pneumoniae:
- 0–6 months: 2%
- 6–12 months: 6%
- 1–5 years: 26%
- 6–12 years: 30%
- 13–18 years: 8%
- 19–64 years: 24%
65 years: 4%
Chlamydia pneumoniae:
- 0–6 months: 1%
- 6–12 months: 3%
- 1–5 years: 47%
- 6–12 years: 31%
- 13–18 years: 4%
- 19–64 years: 13%
65 years: 1%
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
May 2024:
- RSV: 36.5%
- Rhino/Enterovirus: 38.4%
- Rhinovirus: 22.1%
- Influenza A: 20.3%
- Influenza B: 1.3%
- SARS-CoV-2: 7.0%
- Adenovirus: 3.4%
- Parainfluenza 1–4: 7.8%
- Metapneumovirus: 3.9%
June 2024:
- RSV: 31.9%
- Rhino/Enterovirus: 34.7%
- Rhinovirus: 24.3%
- Influenza A: 8.9%
- Influenza B: 5.4%
- SARS-CoV-2: 8.9%
- Adenovirus: 5.4%
- Parainfluenza 1–4: 1.6%
- Metapneumovirus: 5.8%
1–5 Year Age Group
May 2024:
- RSV: 30.8%
- Rhino/Enterovirus: 38.6%
- Rhinovirus: 23.0%
- Influenza A: 46.4%
- Influenza B: 3.8%
- SARS-CoV-2: 11.6%
- Adenovirus: 5.8%
- Parainfluenza 1–4: 3.0%
- Metapneumovirus: 9.4%
June 2024:
- RSV: 17.6%
- Rhino/Enterovirus: 39.7%
- Rhinovirus: 24.9%
- Influenza A: 22.2%
- Influenza B: 9.9%
- SARS-CoV-2: 15.5%
- Adenovirus: 8.6%
- Parainfluenza 1–4: 8.1%
- Metapneumovirus: 7.0%
6–12 Year Age Group
May 2024:
- RSV: 2.4%
- Rhino/Enterovirus: 25.4%
- Rhinovirus: 19.4%
- Influenza A: 45.7%
- Influenza B: 8.2%
- SARS-CoV-2: 2.8%
- Adenovirus: 2.0%
- Parainfluenza 1–4: 2.5%
- Metapneumovirus: 1.8%
June 2024:
- RSV: 5.4%
- Rhino/Enterovirus: 25.4%
- Rhinovirus: 19.4%
- Influenza A: 18.6%
- Influenza B: 22.6%
- SARS-CoV-2: 6.0%
- Adenovirus: 2.2%
- Parainfluenza 1–4: 5.3%
- Metapneumovirus: 3.5%
Summary of Key Age-Specific Trends (June 2024):
- <1 year:
- RSV remains high (31.9%)
- Influenza A decreased (20.3% → 8.9%)
- Influenza B increased (1.3% → 5.4%)
- 1–5 years:
- Influenza A decreased (46.4% → 22.2%)
- Influenza B increased (3.8% → 9.9%)
- 6–12 years:
- Influenza A decreased (45.7% → 18.6%)
- Influenza B increased (8.2% → 22.6%)
Continue Reading